IDT A.I CyberSecurity Scoring
22/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Integrated DNA Technologies in 2026.
No incidents recorded for Integrated DNA Technologies in 2026.
No incidents recorded for Integrated DNA Technologies in 2026.
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Latest updates, reports, and threat intel affecting the global network.
BOULDER, Colo., February 23, 2026--IDT's suite of NGS innovations aim to tackle longstanding bottlenecks in library preparation,...
SUNNYVALE, Calif., February 04, 2026--(BUSINESS WIRE)--Integrated DNA Technologies (IDT), a global leader in genomics, today issued the...
SUNNYVALE, Calif. & EMERYVILLE, Calif., January 14, 2026--IDT and Ansa are joining forces to empower customers with sequence-perfect...
Getting a new credit card number is relatively easy, but you can't get a new genome. In October 2023, 23andMe experienced a data breach...
Tech News News: Microsoft researchers discovered a \"zero-day\" vulnerability in biosecurity screening software using AI, allowing for the...
CORALVILLE, Iowa, September 25, 2025--New enhancer protein expands IDT's market-leading portfolio of HDR reagents, empowering cell and gene...
Former IBM, Microsoft, Amazon and military cybersecurity leaders have combined to introduce a new cyber category — embedding various AI/ML...
Aldevron and Integrated DNA Technologies have successfully manufactured the world's first personalized CRISPR gene editing drug product to treat an infant with...
V irginia takes keeping its tech-talent pond well stocked very seriously. Its Tech Talent Investment Program, for example, is investing $2 billion to double...
A vulnerability in keras-team/keras version 3.15.0 allows unsafe deserialization of attacker-controlled PyTorch pickle data through the public `keras.layers.TorchModuleWrapper.from_config` method. This method invokes `torch.load(..., weights_only=False)` without requiring an explicit unsafe opt-in, such as a `safe_mode=False` parameter. When called outside a `SafeModeScope(True)` context, the absence of an ambient safe mode state permits unsafe deserialization by default. This issue can lead to arbitrary code execution if untrusted Keras layer configurations are processed using this method. The vulnerability arises because the method does not enforce safe deserialization practices unless explicitly guarded by Keras safe mode.
In the Linux kernel, the following vulnerability has been resolved: iommu/amd: Remove latent out-of-bounds access in IOMMU debugfs In iommu_mmio_write() and iommu_capability_write(), the variables dbg_mmio_offset and dbg_cap_offset are declared as int. However, they are populated using kstrtou32_from_user(). If a user provides a sufficiently large value, it can become a negative integer. Prior to this patch, the AMD IOMMU debugfs implementation was already protected by different mechanisms. 1. #define OFS_IN_SZ 8 ensures the user string <= 8 bytes, so e.g. 0xffffffff isn't a valid input. if (cnt > OFS_IN_SZ) return -EINVAL; 2. Implicit type promotion in iommu_mmio_write(), dbg_mmio_offset is int and iommu->mmio_phys_end is u64 if (dbg_mmio_offset > iommu->mmio_phys_end - sizeof(u64)) return -EINVAL; 3. The show handlers would currently catch the negative number and refuse to perform the read. Replace kstrtou32_from_user() with kstrtos32_from_user() to parse the input, and check for negative values to explicitly prevent out-of-bounds memory accesses directly in iommu_mmio_write() and iommu_capability_write().
In the Linux kernel, the following vulnerability has been resolved: sysfs: don't remove existing directory on update failure When sysfs_update_group() is called for a named group and create_files() fails (e.g. -ENOMEM), internal_create_group() calls kernfs_remove(kn) on the group directory. In the update path, kn was obtained via kernfs_find_and_get() and refers to a directory that already existed before this call. Removing it silently destroys a sysfs group that the caller did not create. Only remove the directory if we created it ourselves. On update failure the directory remains as it is left empty by remove_files() inside create_files(), but can be repopulated by a retry.
In the Linux kernel, the following vulnerability has been resolved: mm/damon/sysfs-schemes: call missing mem_cgroup_iter_break() damon_sysfs_memcg_path_to_id() breaks mem_cgroup_iter() loop without calling mem_cgroup_iter_break(). This leaks the cgroup reference. Fix the issue by calling mem_cgroup_iter_break() before the break. The issue was discovered [1] by Sashiko.
In the Linux kernel, the following vulnerability has been resolved: efi: Allocate runtime workqueue before ACPI init Since commit 5894cf571e14 ("acpi/prmt: Use EFI runtime sandbox to invoke PRM handlers") ACPI PRM calls are delegated to a workqueue which runs in a kernel thread, making it easier to detect and mitigate faulting memory accesses performed by the firmware. Rafael reports that such PRM accesses may occur before efisubsys_init() executes, which is where the workqueue is allocated, leading to NULL pointer dereferences. Since acpi_init() [which triggers the early PRM accesses] executes as a subsys_initcall() as well, and has its own dependencies that may be sensitive to initcall ordering, deferring acpi_init() is not an option. So instead, split off the workqueue allocation into its own postcore initcall, as this is the only missing piece to allow EFI runtime calls to be made. This ensures that EFI runtime call (including PRM calls) are accessible to all code running at subsys_initcall() level.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.